CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,851 enrolled
Drug / intervention
Priorix-Tetra™ (MMRV vaccine 208136) +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00578175
NCT00578175Phase 2Completed
CompareCT.gov

Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.

GlaxoSmithKline·interventional·Posted Dec 21, 2007·Updated Oct 9, 2018

In Brief

A Phase 2 clinical trial evaluating Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, and 2 other interventions for Varicella and 3 related conditions. Completed, enrolled 1,851 participants across 141 sites.

Detailed Summary

The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricella, Rubella, Mumps, Measles
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2007
Enrollment StartNov 20, 2007
Primary CompletionFeb 24, 2009
Study CompletionMar 17, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.5 years ago

Interventions

Priorix-Tetra™ (MMRV vaccine 208136)biological

One subcutaneous injection.

ProQuad®biological

One subcutaneous injection.

Havrix®biological

Two intramuscular injections.

Prevnar®biological

One intramuscular injection.